RCEL

SEC source: 0000950170-25-082422 · ownership.xml · derivative · entry 2

Crowe Suzanne · CIK 0001816242 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,295

Underlying: Common Stock · 4,295 shares

Expires 2035-01-21

F4 · derivative.exercise_price: On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

SEC source: 0000950170-25-082422 · ownership.xml · nonDerivative · entry 1

Crowe Suzanne · CIK 0001816242 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,934

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

F2 · balance_after: Includes unvested RSUs.

F3 · balance_after: Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above.

SEC source: 0000950170-25-082417 · ownership.xml · derivative · entry 3

Panaccio Lou · CIK 0001816237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,295

Underlying: Common Stock · 4,295 shares

Expires 2035-01-21

F6 · derivative.exercise_price: On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

SEC source: 0000950170-25-082417 · ownership.xml · nonDerivative · entry 1

Panaccio Lou · CIK 0001816237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,428

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

F2 · balance_after: Includes unvested RSUs.

F3 · balance_after: Includes 70,460 of the Issuer's CDIs. The Reporting Person holds 70,460 CDIs, which translate into 14,092 of the shares of Common Stock set forth above.

SEC source: 0000950170-25-082466 · ownership.xml · derivative · entry 2

Vance Cary Guy · CIK 0001608992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,295

Underlying: Common Stock · 4,295 shares

Expires 2035-01-21

F3 · derivative.exercise_price: On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

SEC source: 0000950170-25-082466 · ownership.xml · nonDerivative · entry 1

Vance Cary Guy · CIK 0001608992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,771

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0000950170-25-082389 · ownership.xml · derivative · entry 1

CORBETT JAMES · CIK 0001238620 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 520,000

Underlying: Common Stock · 520,000 shares

Expires 2035-01-21

F1 · derivative.exercise_price: On January 7, 2025, the Board of Directors approved a grant of 520,000 options to acquire 520,000 shares of Common Stock of the Company (the "Common Stock") to Mr. Corbett, with an effective grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

F2 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date of January 21, 2025.

SEC source: 0000950170-25-082428 · ownership.xml · derivative · entry 2

COOK JEREMY CURNOCK · CIK 0001216486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,295

Underlying: Common Stock · 4,295 shares

Expires 2035-01-21

F3 · derivative.exercise_price: On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

SEC source: 0000950170-25-082428 · ownership.xml · nonDerivative · entry 1

COOK JEREMY CURNOCK · CIK 0001216486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,836

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0000950170-25-082439 · ownership.xml · derivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,295

Underlying: Common Stock · 4,295 shares

Expires 2035-01-21

F3 · derivative.exercise_price: On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

SEC source: 0000950170-25-082439 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,771

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0000950170-25-010560 · ownership.xml · nonDerivative · entry 1

Crowe Suzanne · CIK 0001816242 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,912

F1 · shares: Reflects 2,430 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of the Issuer's common stock and have all the rights and privileges of common stock.

F2 · price: The purchase price was converted from A$4.11, using the exchange rate as in effect on the date of the transaction, and reflects the 5:1 consolidation ratio applied in converting CDIs to shares of the Issuer's common stock.

F3 · balance_after: Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above.

F4 · balance_after: Includes unvested RSUs.

SEC source: 0000950170-24-133748 · ownership.xml · nonDerivative · entry 3

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,734

SEC source: 0000950170-24-133748 · ownership.xml · nonDerivative · entry 2

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,234

SEC source: 0000950170-24-133748 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,759

F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period which began on June 1, 2024 and which ended on November 30, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 3, 2024 (the purchase date of the offering period).

SEC source: 0000950170-24-099134 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,749

SEC source: 0000950170-24-070102 · ownership.xml · derivative · entry 2

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,943

Underlying: Common Stock · 3,943 shares

Expires 2034-06-05

SEC source: 0000950170-24-070102 · ownership.xml · nonDerivative · entry 1

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,989

F1 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0000950170-24-070118 · ownership.xml · derivative · entry 2

Crowe Suzanne · CIK 0001816242 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,943

Underlying: Common Stock · 1 shares

Expires 2034-06-05

SEC source: 0000950170-24-070118 · ownership.xml · nonDerivative · entry 1

Crowe Suzanne · CIK 0001816242 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,426

F1 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date.

F2 · balance_after: Includes unvested RSUs.

F3 · balance_after: Includes 20,560 of the Issuer's CDIs. The Reporting Person's 20,560 CDIs translate into 4,112 of the shares of Common Stock set forth above.

SEC source: 0000950170-24-070155 · ownership.xml · derivative · entry 3

Panaccio Lou · CIK 0001816237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,943

Underlying: Common Stock · 3,943 shares

Expires 2034-06-05

SEC source: 0000950170-24-070155 · ownership.xml · nonDerivative · entry 1

Panaccio Lou · CIK 0001816237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,406

F1 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date.

F2 · balance_after: Includes unvested RSUs.

F3 · balance_after: Includes 70,460 of the Issuer's CDIs. The Reporting Person holds 70,460 CDIs, which translate into 14,092 of the shares of Common Stock set forth above.

SEC source: 0000950170-24-070089 · ownership.xml · derivative · entry 2

Vance Cary Guy · CIK 0001608992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,943

Underlying: Common Stock · 3,943 shares

Expires 2034-06-05

SEC source: 0000950170-24-070089 · ownership.xml · nonDerivative · entry 1

Vance Cary Guy · CIK 0001608992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,749

F1 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0000950170-24-070082 · ownership.xml · derivative · entry 1

CORBETT JAMES · CIK 0001238620 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2034-01-03

F1 · derivative.exercise_price: Pursuant to Mr. Corbett's Employment Agreement, he is eligible for annual equity grants. On January 3, 2024, the Board of Directors approved a grant of 350,000 options to acquire 350,000 shares of Common Stock of the Company to Mr. Corbett, with an effective grant date of January 3, 2024 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on January 3, 2024 of $12.64. The grant was subject to the approval of the Company's stockholders, which was obtained on June 5, 2024.

F2 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date of January 3, 2024.

SEC source: 0000950170-24-070114 · ownership.xml · derivative · entry 2

COOK JEREMY CURNOCK · CIK 0001216486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,943

Underlying: Common Stock · 3,943 shares

Expires 2034-06-05

SEC source: 0000950170-24-070114 · ownership.xml · nonDerivative · entry 1

COOK JEREMY CURNOCK · CIK 0001216486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,814

F1 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0000950170-24-070096 · ownership.xml · derivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,943

Underlying: Common Stock · 3,943 shares

Expires 2034-06-05

SEC source: 0000950170-24-070096 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,749

F1 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0000950170-24-068048 · ownership.xml · nonDerivative · entry 1

Shiroma Donna · CIK 0001816251 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,951

F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period).

F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period).

F2 · balance_after: Includes unvested RSUs

SEC source: 0000950170-24-068006 · ownership.xml · nonDerivative · entry 3

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,974

F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period).

F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period).

SEC source: 0000950170-24-068006 · ownership.xml · nonDerivative · entry 2

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,734

SEC source: 0000950170-24-068006 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,234

SEC source: 0000950170-24-022050 · ownership.xml · nonDerivative · entry 2

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,734

SEC source: 0000950170-24-022050 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,484

SEC source: 0000950170-24-002570 · ownership.xml · derivative · entry 2

Shiroma Donna · CIK 0001816251 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-01-03

F3 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.

SEC source: 0000950170-24-002565 · ownership.xml · derivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning with the first anniversary of the grant date.

SEC source: 0000950170-23-073346 · ownership.xml · nonDerivative · entry 1

CORBETT JAMES · CIK 0001238620 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,580

F1 · shares: Shares sold to cover tax obligation incurred by the Reporting Person upon the vesting of RSUs.

F1 · price: Shares sold to cover tax obligation incurred by the Reporting Person upon the vesting of RSUs.

F2 · balance_after: Includes unvested RSUs

SEC source: 0000950170-23-072730 · ownership.xml · nonDerivative · entry 1

COOK JEREMY CURNOCK · CIK 0001216486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,614

F1 · shares: Shares sold to cover UK tax obligation incurred by the Reporting Person upon the vesting of RSUs

F2 · shares: The original Form 4, filed on December 14, 2023, is being amended by this Form 4 to correct an administrative error, which misreported a sale of common stock to cover taxes for vesting of RSUs on the wrong date. The sale of the stock was reported on December 13, 2023, however, the actual sale occured on December 21, 2023. This Form 4 reflects the correction to the date, price and number of shares sold in the transaction.

F2 · price: The original Form 4, filed on December 14, 2023, is being amended by this Form 4 to correct an administrative error, which misreported a sale of common stock to cover taxes for vesting of RSUs on the wrong date. The sale of the stock was reported on December 13, 2023, however, the actual sale occured on December 21, 2023. This Form 4 reflects the correction to the date, price and number of shares sold in the transaction.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · balance_after: The original Form 4, filed on December 14, 2023, is being amended by this Form 4 to correct an administrative error, which misreported a sale of common stock to cover taxes for vesting of RSUs on the wrong date. The sale of the stock was reported on December 13, 2023, however, the actual sale occured on December 21, 2023. This Form 4 reflects the correction to the date, price and number of shares sold in the transaction.

F4 · balance_after: Includes unvested RSUs

SEC source: 0000950170-23-070445 · ownership.xml · nonDerivative · entry 1

COOK JEREMY CURNOCK · CIK 0001216486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,596

F1 · shares: Shares only sold to cover UK tax obligation incurred by the Reporting Person upon the vesting of RSUs

F1 · price: Shares only sold to cover UK tax obligation incurred by the Reporting Person upon the vesting of RSUs

F2 · balance_after: Includes unvested RSUs

SEC source: 0000950170-23-069750 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,484

SEC source: 0000950170-23-067875 · ownership.xml · nonDerivative · entry 2

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,534

SEC source: 0000950170-23-067875 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,034

F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on July 1, 2023 and ending on November 30, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Company's stock on November 30, 2023 (the purchase date of the offering period).

F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on July 1, 2023 and ending on November 30, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Company's stock on November 30, 2023 (the purchase date of the offering period).

SEC source: 0000950170-24-002570 · ownership.xml · nonDerivative · entry 1

Shiroma Donna · CIK 0001816251 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,726

F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase which began July 1, 2023 and ended November 30, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Company's stock on November 30, 2023 (the purchase date of the offering period).

F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase which began July 1, 2023 and ended November 30, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Company's stock on November 30, 2023 (the purchase date of the offering period).

F2 · balance_after: Includes unvested RSUs

SEC source: 0000950170-23-065502 · ownership.xml · nonDerivative · entry 2

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

SEC source: 0000950170-23-065502 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

SEC source: 0000950170-23-064444 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

SEC source: 0000950170-23-064208 · ownership.xml · nonDerivative · entry 2

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

SEC source: 0000950170-23-064444 · ownership.xml · nonDerivative · entry 2

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,000

SEC source: 0000950170-23-064208 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000